RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 7 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 7

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  2. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  3. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  4. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  5. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  6. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  7. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04316364, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Have previously untreated, pathologically confirmed resectable Stage II, IIIA, or Selected IIIB NSCLC. Staging should be based on the 8th edition of the AJCC/UICC staging system

    Inclusion criterion 2

  3. Women of childbearing age without sterilizing or male, must agree to use contraception or practice abstinence at least 180 days after the last dose of study treatment

    Inclusion criterion 7

  4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

    Inclusion criterion 1

  5. Measurable disease as defined by RECIST v1.1

    Inclusion criterion 5

  6. Malignancies other than NSCLC within 5 years prior to randomization

    Exclusion criterion 3

    Has a known history of human immunodeficiency virus (HIV) infection

    Exclusion criterion 8

  7. Pregnant or lactating women

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04316364, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Have previously untreated, pathologically confirmed resectable Stage II, IIIA, or Selected IIIB NSCLC. Staging should be based on the 8th edition of the AJCC/UICC staging system
  • Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent
  • Adequate tumor tissue sample blocks for central programmed death-ligand 1 (PD-L1) testing
  • Measurable disease as defined by RECIST v1.1
  • Adequate organ function
  • Women of childbearing age without sterilizing or male, must agree to use contraception or practice abstinence at least 180 days after the last dose of study treatment

Exclusion Criteria:

  • Any previous systematic anti-cancer therapy for lung cancer
  • With active, known or suspected autoimmune disease of autoimmune disease
  • Malignancies other than NSCLC within 5 years prior to randomization
  • Has or suspected has a history of pneumonitis /interstitial lung disease or any serve lung diseases which will influence the examination of lung function
  • Significant history of cardiovascular and cerebrovascular disease
  • Significant haemorrhagic disease
  • Has an arteriovenous thrombotic events
  • Has a known history of human immunodeficiency virus (HIV) infection
  • Has a known active Hepatitis B or Hepatitis C
  • Allergic to monoclonal antibodies or other protein drugs
  • Allergic to the intervention regimens
  • Pregnant or lactating women
  • Has known psychiatric or substance abuse disorders
  • Confirmed COVID-19 infection or suspected COVID-19 infection or close contact with a person with known or suspected COVID-19 infection.

Quoted from ClinicalTrials.gov, NCT04316364, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04316364, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04316364